WINNIPEG, Manitoba - (April 30, 2004) - Medicure
Inc. (TSX: MPH / Amex: MCU), a cardiovascular drug discovery and
development company, is pleased to announce that it has been selected
to present at two major biotech conferences in May. On May 12, 2004,
Medicure will be making a corporate presentation at the Rodman &
Renshaw Techvest Global Healthcare Conference in London, England,
and also on May 12, the Company will present at the BioFinance 2004
Conference in Toronto.
The London Conference, the first of two Rodman & Renshaw Techvest
Global Healthcare Conferences - the second is in New York in October
- will bring together medical and scientific experts and executives
from the European and North American biotechnology and pharmaceutical
industries, along with institutional investors, analysts and venture
capitalists following the life sciences sector. Corporate presentations
will be delivered from leading biotech companies from around the
world. Albert D. Friesen, Ph.D., Medicure's President and CEO will
deliver the Company's presentation at 9:25 a.m., London time. His
presentation will be 20 minutes in duration and will be followed
by a 30-minute breakout session and one-on-one meetings.
In the afternoon of May 12, Dawson Reimer, Medicure's Vice-President
of Operations, will make a corporate presentation at BioFinance
2004, Canada's largest annual life sciences business gathering.
Medicure's presentation will commence at 2 p.m. Eastern Time in
the Trinity I Meeting Room of the Marriott Hotel in downtown Toronto.
BioFinance 2004 will feature presentations from more than 120 Canadian,
U.S. and European public and private sector life science companies.
More than 700 delegates, including investment bankers, institutional
investors, pension fund managers, venture capitalists, analysts
and professional service firms, will attend the conference.
"We are pleased to have the opportunity to present the Medicure
story to audiences at these two important biotech conferences,"
said Dr. Friesen, Ph.D. "We have had a very exciting start
to 2004 and we look forward to our participation on the world stage
at conferences of this stature.
"Our involvement in these conferences reflects the growing
recognition of Medicure internationally and they represent exceptional
venues for reaching sophisticated groups of institutional investors,
investment bankers and financial analysts," he added. "They
also allow us to broaden Medicure's exposure and enhance our visibility
in the Canadian, U.S. and European markets."
About Medicure Inc.
Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia, ischemic
reperfusion injury, and stroke. The cardiovascular and stroke market
is the largest pharmaceutical sector with annual global sales of
over US $70 billion.
The Company's second product candidate, MC-4232, is being targeted
for the treatment of hypertension, a common disorder in which blood
pressure remains abnormally high. Approximately 73% of the more
than 50 million adult Americans who have hypertension, are not adequately
treated.
Medicure also has a medicinal chemistry based Drug Discovery program
focused on discovery and advancement of novel small molecule, anti-ischemics
and anti-thrombotics towards human clinical studies.
This news release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
